20351-79-5

Basic information

• Product Name: 8-Methoxy-4-chromanone
• Synonyms: 8-Methoxy-4-chromanone;8-MethoxychroMan-4-one;8-methoxy-2,3-dihydrochromen-4-one
• CAS NO: 20351-79-5
• Molecular Formula: C₁₀H₁₀O₃
• Molecular Weight: 178.1846
• Mol File: 20351-79-5.mol

Chemical Properties

• Melting Point: 89 °C
• Boiling Point: 319.9°C at 760 mmHg
• Flash Point: 138.3°C
• Appearance: /
• Density: 1.205g/cm³
• Vapor Pressure: 0.000329mmHg at 25°C
• Refractive Index: 1.546
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 8-Methoxy-4-chromanone(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Methoxy-4-chromanone(20351-79-5)
• EPA Substance Registry System: 8-Methoxy-4-chromanone(20351-79-5)

Safety Data

• Hazardous Substances Data: 20351-79-5(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
8-Methoxy-4-chromanone is used as a chemical intermediate for the synthesis of various compounds. Its presence of functional groups such as aldehyde and ether makes it a versatile building block in the preparation of complex molecules.
Used in Pharmaceutical Research:
8-Methoxy-4-chromanone is used as a research compound in the development of new pharmaceuticals. Its unique structure and properties may offer potential applications in drug discovery, although more research is needed to explore its therapeutic potential.
Used in Material Science:
8-Methoxy-4-chromanone is used as a component in the development of new materials. Its chemical properties may contribute to the creation of novel materials with specific characteristics, such as improved stability or enhanced reactivity.
Used in Analytical Chemistry:
8-Methoxy-4-chromanone is used as a reference compound in analytical chemistry for the calibration of instruments and the development of new analytical methods. Its distinct chemical properties can serve as a benchmark for comparison in various analytical techniques.
Note: The specific applications mentioned above are hypothetical and are provided as examples to illustrate the potential uses of 8-Methoxy-4-chromanone. Further research and development are required to validate these applications and explore additional uses in different industries.

InChI:InChI=1/C10H10O3/c1-12-9-4-2-3-7-8(11)5-6-13-10(7)9/h2-4H,5-6H2,1H3

Upstream product

• 117543-36-9 4-chloro-8-methoxychromene 
• 117543-24-5 1-(3-Chloro-prop-2-ynyloxy)-2-methoxy-benzene 
• 70786-42-4 3-(o-methoxyphenoxy)propionitrile 
• 90-05-1 2-methoxy-phenol 
• 41580-71-6 1-methoxy-2-(prop-2-ynyloxy)benzene 
• 10026-13-8 phosphorus pentachloride 
• 20370-80-3 3-(2-methoxyphenoxy)propanoic acid 
• 71-43-2 benzene 

Downstream Products

• 711-69-3 9-methoxy-3,4-dihydro-2H-benzo[f][1,4]oxazepin-5-one 
• 192575-55-6 8-Methoxy-3-(2-hydroxybenzyl)-chroman-4-one 
• 59208-25-2 8-Methoxy-3-(2-hydroxybenzyl)-chromanol 
• 1843-90-9 8-hydroxychroman-4-one 

Relevant articles and documents

Acid activated montmorillonite K-10 mediated intramolecular acylation: Simple and convenient synthesis of 4-chromanones

3-Aryloxyproionic acids undergo intramolecular cyclization in the presence of AA.Mont.K-10 in toluene under reflux for 30–45 min in good to excellent yields. Phenyl ring bearing various substituents at the ortho, meta, para positions undergo this cyclization reaction. This method involves simple work up and amenable for large scale preparations. The heterogeneous acid treated catalyst can be regenerated and used for up to three cycles with minimum loss of activity.

ALPHA, BETA-UNSATURATED AMIDE COMPOUND

An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like: [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

a, ? UNSATURATED AMIDE COMPOUND

The present invention provides an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like represented by the following formula (I): [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

Analogues of σ receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4- tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with added polar functionality and reduced lipophilicity for potential use as positron emission tomography radiotracers

1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl] piperazine 1 (PB28) represents an excellent lead candidate for therapeutic and/or diagnostic applications in oncology. However, because its utility is limited by its relatively high de

THERMAL BEHAVIOUR OF ARYL γ-HALOPROPARGYL ETHERS

A systematic study of the behaviour of aryl γ-halopropargyl ethers under thermal condition was undertaken.Aryl γ-bromopropargyl ethers 2 underwent unique transformation in N,N-diethylaniline (215 deg C, 6 h) giving rise to a mixture of products 3,4 and 5,whereas, under similar conditions aryl γ-chloropropargyl ethers 8, afforded 4-chlorochromenes, 9.A remarkable substituent and solvent effect has been observed in the thermolysis of these aryl γ-bromo and γ-chloropropargyl ethers, rendering this transformation as a method for the synthesis of a number of substituted 4-bromochromenes 3, 4-chlorochromenes 9 and chroman-4-ones 7.In contrast, solution thermolysis of aryl γ-iodopropargyl ether 11 afforded aryl propargyl ether 1 as the major product.

A SIMPLE ROUTE FOR THE SYNTHESIS OF 4-CHLOROCHROMENES AND CHROMAN-4-ONES

A one pot synthesis of a number of 4-chlorochromenes and chroman-4-ones was achived from γ-chloropropargyl aryl ethers proceeding through Claisen rearrangement, depending upon the solvent of choice.